View abstract

Cet abstract a été assigné à session AOB Free Papers 1

Type de présentation	Oral presentation
Titre	Have we gone down a new road with Akantior® in the treatment of Acanthamoeba keratitis?

But	This case series evaluates the efficacy and tolerability of Akantior® (polyhexanide 0.08%) as a novel treatment for Acanthamoeba keratitis.
Méthodes	Four patients with confirmed Acanthamoeba keratitis were treated with Akantior® at the University Hospital Leuven between 2024-2025.
Résultats	Following treatment with Akantior®, two of the four patients showed complete remission of their infectious keratitis. The third patient discontinued therapy due to intolerance, with worsening symptoms reporting increased irritation and conjunctival hyperaemia. The fourth patient who was recently initiated on Akantior® is currently closely monitored.
Conclusion	The novel drug Akantior® (polyhexanide 0.08%) works through two mechanisms: it disrupts the outer membrane of the Acanthamoeba cell, causing cell death; while also damaging the genetic material, preventing replication. Previous research shows that polyhexanide 0.08% monotherapy is non-inferior, and potentially even superior, to currently used dual therapy (polyhexanide 0.02% plus propamidine). The commercial availability of Akantior® provides an important advantage over compounded formulations, moreover as polyhexanide is currently not available in Belgium as raw material. The validation of clinical results, together with pricing and potential reimbursement in Belgium, will determine whether Akantior® secures its long-term position in the field.
Conflit d'intérêt	Non

Auteurs 1

Initiales	E
Nom	Verleyen
Institut	UZ Leuven
Ville	Leuven

Auteurs 2

Initiales	H
Nom	Delbeke
Institut	UZ Leuven
Ville	Leuven